Lebrikizumab Effective for Adults, Teens With Atopic Dermatitis
In two phase 3 trials, lebrikizumab effective for primary outcome of IGA score of 0 or 1 and for achieving EASI-75
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.